| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Defb4 |
| Uniprot No | Q8WTQ1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-72aa |
| 氨基酸序列 | EFELDRICGYGTARCRKKCRSQEYRIGRCPNTYACCLRKWDESLLNRTKP |
| 预测分子量 | 6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Defb4(β-defensin 4)重组蛋白的模拟参考文献示例(注：内容为虚构，仅作格式参考)：
---
1. **标题**: *Recombinant Defb4 exhibits broad-spectrum antimicrobial activity against multidrug-resistant pathogens*
**作者**: Smith A, et al.
**摘要**: 本研究通过大肠杆菌表达系统成功制备重组Defb4蛋白，证明其对耐甲氧西林金黄色葡萄球菌(MRSA)和铜绿假单胞菌具有显著抑菌活性，并揭示其通过破坏细菌膜结构发挥作用的机制。
2. **标题**: *Defb4 recombinant protein modulates inflammatory response in a murine colitis model*
**作者**: Chen L, et al.
**摘要**: 通过动物实验发现，重组Defb4可减轻小鼠结肠炎模型的炎症反应，降低促炎因子(如TNF-α和IL-6)表达，提示其在免疫调节和炎症性疾病治疗中的潜在应用。
3. **标题**: *Structural and functional characterization of human Defb4 produced in yeast expression system*
**作者**: González R, et al.
**摘要**: 采用酵母表达系统高效表达Defb4重组蛋白，通过核磁共振(NMR)解析其三维结构，并验证其与CCR6受体的特异性结合能力，为基于防御素的药物设计提供结构基础。
4. **标题**: *Defb4 enhances wound healing by promoting keratinocyte migration and angiogenesis*
**作者**: Tanaka K, et al.
**摘要**: 体外和体内实验表明，重组Defb4通过激活EGFR/Akt信号通路加速皮肤创面愈合，同时促进血管生成，为慢性伤口治疗提供了新策略。
---
注：以上文献为模拟内容，实际研究中建议通过PubMed、Google Scholar等平台检索关键词(如“Defb4 recombinant protein”或“human beta-defensin 2”)获取真实文献。
**Background on Defb4 Recombinant Protein**
Defb4 (Defensin beta 4), also known as human β-defensin 2 (hBD-2), is a small cationic antimicrobial peptide encoded by the *DEFB4A* gene. It belongs to the β-defensin family, a critical component of the innate immune system, primarily involved in host defense against pathogens. Defb4 is constitutively expressed or induced in epithelial cells of barrier tissues (e.g., skin, respiratory tract, and oral mucosa) and immune cells, particularly under inflammatory conditions or microbial challenge. Its production is regulated by signaling pathways such as NF-κB, often triggered by Toll-like receptor (TLR) activation or proinflammatory cytokines like IL-1β and TNF-α.
Functionally, Defb4 exhibits broad-spectrum antimicrobial activity against bacteria, fungi, and enveloped viruses by disrupting microbial membranes via electrostatic interactions. Beyond direct pathogen killing, it acts as a chemokine, recruiting immune cells (e.g., dendritic cells, T cells) via CCR6 receptor binding, thereby bridging innate and adaptive immunity. Dysregulation of Defb4 has been implicated in diseases like psoriasis, atopic dermatitis, and chronic infections, where its expression is either elevated or suppressed, influencing disease progression.
Recombinant Defb4 is engineered using biotechnological platforms (e.g., bacterial or mammalian expression systems) to produce purified, bioactive peptides for research and therapeutic development. Its recombinant form retains structural integrity, including conserved cysteine motifs critical for disulfide bond formation and functionality. Studies explore its potential in combating antibiotic-resistant infections, modulating immune responses, and enhancing wound healing. However, challenges like peptide stability, delivery efficiency, and off-target effects in complex biological environments remain hurdles for clinical translation. Current research continues to unravel its pleiotropic roles and optimize its application in antimicrobial and immunotherapeutic strategies.
×
